KURA vs SNDX
KURA: Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships. SNDX: Syndax Pharmaceuticals is a clinical-stage and commercial-stage biotechnology company developing a pipeline of targeted cancer therapies, including approved treatments for leukemia and chronic graft-versus-host disease.
Side-by-side fundamentals
| Metric | KURA | SNDX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.54 | $22.05 | |
| Market cap as of 2026-07-23 | $944M | $2.0B | |
| PEG as of 2026-07-23 | -0.05 | n/a | |
| Net margin as of 2026-07-23 | -411.2% | -111.9% | SNDX higher |
| Gross margin as of 2026-07-23 | +99.9% | +96.0% | KURA higher |
| Operating margin as of 2026-07-23 | -443.5% | -102.8% | SNDX higher |
| ROE as of 2026-07-23 | -141.9% | -256.7% | KURA higher |
| ROA as of 2026-07-23 | -43.3% | -45.3% | KURA higher |
| Debt / equity as of 2026-07-23 | 0.09 | 8.26 | KURA lower |
| Revenue growth (YoY) as of 2026-07-23 | +29.5% | +397.3% | SNDX higher |
| Beta as of 2026-07-23 | 0.37 | 0.35 | |
| 1-year return as of 2026-07-22 close | +58.0% | +113.9% | SNDX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.